CGC vs. USNA, CRON, MNMD, BTMD, ACB, CDXC, IMTX, AORT, TYRA, and BCYC
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include USANA Health Sciences (USNA), Cronos Group (CRON), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Immatics (IMTX), Artivion (AORT), Tyra Biosciences (TYRA), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
USANA Health Sciences (NYSE:USNA) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
54.3% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 0.3% of USANA Health Sciences shares are owned by insiders. Comparatively, 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
USANA Health Sciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
USANA Health Sciences received 375 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 60.68% of users gave USANA Health Sciences an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
In the previous week, Canopy Growth had 6 more articles in the media than USANA Health Sciences. MarketBeat recorded 8 mentions for Canopy Growth and 2 mentions for USANA Health Sciences. Canopy Growth's average media sentiment score of 0.96 beat USANA Health Sciences' score of 0.80 indicating that USANA Health Sciences is being referred to more favorably in the media.
USANA Health Sciences currently has a consensus price target of $46.00, suggesting a potential downside of 6.10%. Canopy Growth has a consensus price target of $4.87, suggesting a potential downside of 55.15%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities analysts plainly believe USANA Health Sciences is more favorable than Canopy Growth.
USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences has a net margin of 6.88% compared to USANA Health Sciences' net margin of -326.75%. Canopy Growth's return on equity of 12.80% beat USANA Health Sciences' return on equity.
Summary
USANA Health Sciences beats Canopy Growth on 14 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
